Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy

NCT ID NCT07520045

Recruiting now Knowledge-focused Sponsor: Osijek University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two eye injections—faricimab and a biosimilar version of ranibizumab—in 100 adults with diabetic retinopathy. Researchers will use eye scans (OCT and OCT angiography) to see which drug leads to better early changes in the retina after three monthly doses. The goal is to find imaging markers that predict who responds best to each treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: faricimab and biosimilar ranibizumab (eye injections)
What this could lead to: If successful, this study could help doctors choose the best eye injection for each patient with diabetic retinopathy based on early imaging signs.
What could go wrong: This is a small, early-stage study (100 people) that only looks at imaging changes after three doses. It does not test long-term vision outcomes or safety, so results may not change practice directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic macular edema diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC MACULAR EDEMA (DME) DIABETIC RETINOPATHY, DR

Contacts and locations

Locations

University Hospital Osijek
RECRUITING

Osijek, 31000, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.